## CHEERS checklist for PHI JP HO-16-17837

| · · · · · · · · · · · · · · · · · · ·                           | em #. | Recommendation   | reported on |
|---|-------|--|-------------|
| Title and abstract  | T -   |  | lines       |
| Title   | 1     | Identify the study as an economic evaluation or use more specific terms such as "cost-effectiveness analysis", and describe the interventions compared.  | NA          |
| Abstract  | 2     | Provide a structured summary of objectives, perspective, setting,<br>methods (including study design and inputs), results (including<br>base case and uncertainty analyses), and conclusions.  | 25-48       |
| Introduction  |       |  |             |
| Background and objectives                                       | 3     | Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions.  | 54-112      |
| Methods   | •     |  |             |
| Target<br>population and<br>subgroups                           | 4     | Describe characteristics of the base case population and subgroups analysed, including why they were chosen  | 124-28      |
| Setting and location  | 5     | State relevant aspects of the system(s) in which the decision(s) need(s) to be made.   | NA          |
| Study perspective   | 6     | Describe the perspective of the study and relate this to the costs being evaluated.  | NA          |
| Comparators   | 7     | Describe the interventions or strategies being compared and state why they were chosen.  | 129-32      |
| Time horizon  | 8     | State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.   | 124-26      |
| Discount rate   | 9     | Report the choice of discount rate(s) used for costs and outcomes and say why appropriate  | NA          |
| Choice of health<br>outcomes                                    | 10    | Describe what outcomes were used as the measure(s) of benefit<br>in the evaluation and their relevance for the type of analysis<br>performed.  | 196-98      |
| Measurement of effectiveness                                    | 11a   | Single study-based estimates: Describe fully the design features<br>of the single effectiveness study and why the single study was a<br>sufficient source of clinical effectiveness data.  | NA          |
|   | 11b   | Synthesis-based estimates: Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.  | 151-88      |
| Measurement<br>and valuation of<br>preference-based<br>outcomes | 12    | If applicable, describe the population and methods used to elicit preferences for outcomes   | NA          |
| Estimating<br>resources and<br>costs                            | 13a   | Single study-based economic evaluation: Describe approaches<br>used to estimate resource use associated with the alternative<br>interventions. Describe primary or secondary research methods<br>for valuing each resource item in terms of its unit cost. Describe<br>any adjustments made to approximate to opportunity costs.   | NA          |
|   | 13b   | Model-based economic evaluation: Describe approaches and<br>data sources used to estimate resource use associated with<br>model health states. Describe primary or secondary research<br>methods for valuing each resource item in terms of its unit cost.<br>Describe any adjustments made to approximate to opportunity<br>costs | NA          |
| Currency, price<br>dates and<br>conversion                      | 14    | Report the dates of the estimated resource quantities and unit<br>costs. Describe methods for adjusting estimated unit costs to the<br>year of reported costs if necessary. Describe methods for<br>converting costs into a common currency base and the exchange  | NA          |

|                   |     | rate  |              |
|-------------------|-----|---|--------------|
| Choice of model   | 15  | Describe and give reasons for the specific type of decision-        | 115-23       |
|                   |     | analytical model used. Providing a figure to show model             |              |
|                   |     | structure is strongly recommended.                                  |              |
| Assumptions       | 16  | Describe all structural or other assumptions underpinning the       | 117-23, 151- |
|                   |     | decision-analytical model   | 52, 173-79,  |
|                   |     |   | 189-94       |
| Analytical        | 17  | Describe all analytical methods supporting the evaluation. This     | 202-11       |
| methods           |     | could include methods for dealing with skewed, missing, or          |              |
|                   |     | censored data; extrapolation methods; methods for pooling           |              |
|                   |     | data; approaches to validate or make adjustments (such as half      |              |
|                   |     | cycle corrections) to a model; and methods for handling             |              |
|                   |     | population heterogeneity and uncertainty                            |              |
| Results           |     |   |              |
| Study parameters  | 18  | Report the values, ranges, references, and, if used, probability    | 217-38       |
|                   |     | distributions for all parameters. Report reasons or sources for     |              |
|                   |     | distributions used to represent uncertainty where appropriate.      |              |
|                   |     | Providing a table to show the input values is strongly              |              |
|                   |     | recommended   |              |
| Incremental costs | 19  | For each intervention, report mean values for the main              | 221-24, 231- |
| and outcomes      |     | categories of estimated costs and outcomes of interest, as well     | 37           |
|                   |     | as mean differences between the comparator groups. If               |              |
|                   |     | applicable, report incremental cost-effectiveness ratios            |              |
| Characterizing    | 20a | Single study-based economic evaluation: Describe the effects of     | NA           |
| uncertainty       |     | sampling uncertainty for the estimated incremental cost and         |              |
| -                 |     | incremental effectiveness parameters, together with the impact      |              |
|                   |     | of methodological assumptions (such as discount rate, study         |              |
|                   |     | perspective).   |              |
|                   | 20b | Model-based economic evaluation: Describe the effects on the        | 239-48       |
|                   |     | results of uncertainty for all input parameters, and uncertainty    |              |
|                   |     | related to the structure of the model and assumptions               |              |
| Characterizing    | 21  | If applicable, report differences in costs, outcomes, or cost-      | NA           |
| heterogeneity     |     | effectiveness that can be explained by variations between           |              |
| <u> </u>          |     | subgroups of patients with different baseline characteristics or    |              |
|                   |     | other observed variability in effects that are not reducible by     |              |
|                   |     | more information  |              |
| Discussion        |     |   |              |
| Study findings,   | 22  | Summarise key study findings and describe how they support the      | 250-314      |
| limitations,      |     | conclusions reached. Discuss limitations and the generalisability   |              |
| generalizability  |     | of the findings and how the findings fit with current knowledge     |              |
| and current       |     |   |              |
| knowledge         |     |   |              |
| Other             |     |   |              |
| Source of funding | 23  | Describe how the study was funded and the role of the funder in     | 321-24       |
|                   |     | the identification, design, conduct, and reporting of the analysis. |              |
|                   |     | Describe other non-monetary sources of support                      |              |
| Conflicts of      | 24  | Describe any potential for conflict of interest of study            | 326-28       |
| interest          |     | contributors in accordance with journal policy. In the absence of   |              |
|                   |     | a journal policy, we recommend authors comply with                  |              |
|                   |     | International Committee of Medical Journal Editors                  |              |
|                   |     | recommendations   |              |